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PCV133 THE COST-EFFECTIVENESS OF GENOTYPING CYP2C19 TO GUIDE ANTIPLATELET THERAPY SELECTION
Reese ES 1 , Mullins CD 1 , Beitelshees AL 2 , Onukwugha E 1 1 University of Maryland School of Pharmacy, Baltimore, MD, USA, 2 University of Maryland, Baltimore, Baltimore, MD, USA OBJECTIVES: The recent re-label of clopidogrel to include information on CYP2C19 genotype and the approval of a second-generation antiplatelet medication, prasugrel, could greatly impact the way antiplatelet therapy is prescribed. This study assesses the cost-effectiveness of genotyping patients to guide selection of antiplatelet therapy with clopidogrel or prasugrel. METHODS: A decision tree was created using prevalence of CYP2C19 metabolism status, cardiovascular events, and bleeding events and costs of events as reported in the literature and publically available FDA advisory committee documents. In the genotype arm, an individual's metabolic status determined medication selection. Effect was defined as the cost per event avoided. Scenario analyses that were conducted to determine the robustness of the model included scenario A: clopidogrel use without genotyping and scenario B: prasugrel use without genotyping. Number needed to genotype to avoid one cardiovascular or bleeding event from occurring was also determined. RESULTS: The probability of being an ultra-rapid or extensive metabolizer of CYP2C19 was 73% and the probability of being an intermediate or poor metabolizer was 27%. For the no-genotype arm, the estimated proportions of medication selection used were 70% to receive clopidogrel and 30% to receive prasugrel. The model favored the intervention of genotyping patients to determine antiplatelet therapy (ICER: −$20,049). Both scenario analyses exhibited a dominant strategy of genotyping patients (ICERA: −$21,833 and ICERB: −$15,918). Number needed to genotype to avoid one bleeding or cardiovascular event was 26.
CONCLUSIONS:
The cost-effectiveness analysis suggests it is more effective and less costly to genotype patients prior to selecting clopidogrel or prasugrel for the patient's antiplatelet therapy. Patients who self-discharge against medical advice (AMA) may be at higher risk for a hospital readmission if the unauthorized discharge was premature. The study objective is to examine the relationship between discharges AMA and cardiovascular disease (CVD) hospital readmissions while addressing bias due to potential confounding, selection, and hospital-level clustering. METHODS: This cross-sectional study uses confidential inpatient hospital discharge data covering the years 2000 to 2005. The outcome variables captured readmissions for a CVD-related condition following an index CVD-related admission. The covariate of interest was an indicator variable for a discharge AMA in the index hospitalization. The relationship between discharges AMA and 7-day, 31-day, 180-day, and 365-day hospital readmissions was examined using generalized linear models with adjustments for clustering and selection bias. RESULTS: The sample included 443,088 patients, of which 22,757 (5.1%) were readmitted to the same hospital. Approximately 1% of the patients who were readmitted in the hospital during the study period left AMA on the index admission while 0.89% of those who were not readmitted left AMA (p = 0.047). The odds of a CVD-related readmission within 7 days, 31 days, 180 days and 365 days were 145% (p < 0.001), 55% (p < 0.001), 26% (p < 0.001) and 15% (p = 0.0011) higher for patients discharged AMA on index admission compared to those who were discharged formally. Results are robust to corrections for observable selection bias (via propensity score analysis) and hospital-level clustering. CONCLU-SIONS: A self-discharge AMA among patients admitted for CVD is predictive of CVD-related readmissions and the strength of association increases as the time between admissions decreases.
PCV134 READMISSIONS AFTER UNAUTHORIZED DISCHARGES IN THE CARDIOVASCULAR SETTING

PCV135 TREATMENT PATTERNS IN ATRIAL FIBRILLATION: AGENTS USED IN CURRENT PATIENT MANAGEMENT
Emons MF 1 , Lin J 2 , Yu HT 1 1 Cerner LifeSciences, Beverly Hills, CA, USA, 2 Sanofi-Aventis, Bridgewater, NJ, USA OBJECTIVES: Future refinement of pharmacotherapy of atrial fibrillation/atrial flutter (AF) requires a detailed understanding of how treatments are currently employed in clinical practice. METHODS: In this retrospective cohort study, we used the US MarketScan ® database to identify patients ≥18 years with AF (≥1 AF inpatient or ≥2 outpatient AF claims) and ≥18 months' continuous enrollment data between Jan 2003 and Sept 2007. The first qualifying AF diagnosis following 12 months' enrollment was designated the index diagnosis. AF was classified as newly-diagnosed (ND) or preexisting (PRE), based on treatment history in the pre-index period. RESULTS: Of 184,155 identified patients (mean age 73 years, 55% men), 64,669 had ND and 119,486 had PRE AF. Non-pharmacotherapy for AF was undertaken in 11% of patients with ND vs 6% of patients with PRE disease, most commonly cardioversion (9% vs. 4% of patients, respectively). Across both patient groups, 30% received no drug therapy within 30 days of initial AF diagnosis (initial treatment), 17% received antiarrhythmics (rhythm-control agents), 51% rate-control agents, 40% anticoagulants, and 5% antiplatelets (aspirin use was not captured). Median duration of uninterrupted initial therapy was 210 days for antiarrhythmics and antiplatelets, 228 days for anticoagulants and 420 days for rate-control agents. Over the entire post-index follow-up period (mean 20 months), ND and PRE AF patients received antiarrhythmics (27% vs 28%), rate-control agents (77% vs 76%), anticoagulants (54% vs. 66%) and antiplatelets (14% vs. 10%). Overall, the most commonly used drugs were amiodarone (15%), β-blockers (56%), calcium channel blockers (23%), cardiac glycosides (35%), warfarin (61%) and clopidogrel (11%). CONCLUSIONS: Non-pharmacological interventions for AF were relatively uncommon. Almost one-third of AF patients in our study remained untreated for the first 30 days after diagnosis, which may represent under-treatment. Rate-control agents and anticoagulants were used more frequently than antiarrhythmics and antiplatelets for treatment of AF.
PCV136 PRIORITY-SETTING FOR COMPARATIVE EFFECTIVENESS RESEARCH
Seidenfeld JD, Montgomery RW, Sonnad S Center for Medical Technology Policy, Baltimore, MD, USA OBJECTIVES: Coincident with the increasing focus on comparative effectiveness research (CER), a number of organizations have begun to engage in prioritizing topics for CER. This paper presents the priority-setting process developed by the Center for Medical Technology Policy (CMTP) and its application to the selection of cardiac technologies. METHODS: We reviewed criteria and processes used by other organizations. We then developed a multi-stage process including, 1) horizon scanning; 2) topic nomination; 3) expert solicitation; 4) topic review and selection; 5) criteria application and discussion by a expert workgroup, and 6) final ranking of topics for varied research projects. After internally refining a broad list to the top ten technologies, we convened an expert workgroup charged with ranking these top technologies using prospectively developed criteria. Experts were provided with a list of criteria and briefs summarizing clinical, economic, and ethical aspects of each technology. RESULTS: Topic nomination produced an initial list of approximately 40 technologies, which were narrowed to the top ten based on suitability for CMTP's coverage with evidence development (CED) initiatives and guidelines
